Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86,062 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.
Eroglu Z, Broman KK, Thompson JF, Nijhuis A, Hieken TJ, Kottschade L, Farma JM, Hotz M, Deneve J, Fleming M, Bartlett EK, Sharma A, Dossett L, Hughes T, Gyorki DE, Downs J, Karakousis G, Song Y, Lee A, Berman RS, van Akkooi A, Stahlie E, Han D, Vetto J, Beasley G, Farrow NE, Hui JYC, Moncrieff M, Nobes J, Baecher K, Perez M, Lowe M, Ollila DW, Collichio FA, Bagge RO, Mattsson J, Kroon HM, Chai H, Teras J, Sun J, Carr MJ, Tandon A, Babacan NA, Kim Y, Naqvi M, Zager J, Khushalani NI. Eroglu Z, et al. Among authors: kim y. J Immunother Cancer. 2022 Aug;10(8):e004417. doi: 10.1136/jitc-2021-004417. J Immunother Cancer. 2022. PMID: 36002183 Free PMC article.
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Khushalani NI, et al. Among authors: kim y. J Immunother Cancer. 2022 Nov;10(11):e005684. doi: 10.1136/jitc-2022-005684. J Immunother Cancer. 2022. PMID: 36450385 Free PMC article. Clinical Trial.
Biomarkers.
Cha WJ, Yi D, Chumin EJ, Byun MS, Jung JH, Ahn H, Kim YK, Lee YS, Kang KM, Sohn CH, Risacher SL, Sporns O, Nho K, Saykin AJ, Lee DY; KBASE Research Group. Cha WJ, et al. Among authors: kim yk. Alzheimers Dement. 2024 Dec;20 Suppl 2:e090633. doi: 10.1002/alz.090633. Alzheimers Dement. 2024. PMID: 39786070
Biomarkers.
Jeon SY, Yi D, Byun MS, Kong N, Jung JH, Chang YY, Keum M, Ahn H, Lee JY, Lee YS, Kim YK, Kang KM, Sohn CH, Lee YJ, Lee DY; KBASE Research Group. Jeon SY, et al. Among authors: kim yk. Alzheimers Dement. 2024 Dec;20 Suppl 2:e088948. doi: 10.1002/alz.088948. Alzheimers Dement. 2024. PMID: 39786004
Biomarkers.
Lee EH, Kang SH, Kim YJ, Zetterberg H, Blennow K, Gonzalez-Ortiz F, Shin D, Yoo H, Cheon BK, Kim JP, Kim HJ, Na DL, Jang H, Seo SW. Lee EH, et al. Among authors: kim yj. Alzheimers Dement. 2024 Dec;20 Suppl 2:e087856. doi: 10.1002/alz.087856. Alzheimers Dement. 2024. PMID: 39785977
Biomarkers.
Choi H, Byun MS, Yi D, Jung JH, Sohn BK, Keum M, Jung G, Ahn H, Lee JY, Lee YS, Kim YK, Lee DY; KBASE Research Group. Choi H, et al. Among authors: kim yk. Alzheimers Dement. 2024 Dec;20 Suppl 2:e088148. doi: 10.1002/alz.088148. Alzheimers Dement. 2024. PMID: 39784416
86,062 results
You have reached the last available page of results. Please see the User Guide for more information.